Venetoclax is safe and efficacious in relapsed/refractory AML

Chezi Ganzel; Ron Ram; Alexander Gural; Ofir Wolach; Sharon Gino-Moor; Vladimir Vainstein; Boaz Nachmias; Arie Apel; Maya Koren-Michowitz; Oren Pasvolsky; Ronit Yerushalmi; Ivetta Danylesko; Yosef Cohen; Galit Peretz; Yakir Moshe; Miri Zektser; Shay Yeganeh; Jacob M. Rowe; Yishai Ofran

doi:10.1080/10428194.2020.1761964

Venetoclax is safe and efficacious in relapsed/refractory AML

Chezi Ganzel^*, Ron Ram, Alexander Gural, Ofir Wolach, Sharon Gino-Moor, Vladimir Vainstein, Boaz Nachmias, Arie Apel, Maya Koren-Michowitz, Oren Pasvolsky, Ronit Yerushalmi, Ivetta Danylesko, Yosef Cohen, Galit Peretz, Yakir Moshe, Miri Zektser, Shay Yeganeh, Jacob M. Rowe, Yishai Ofran

^*Corresponding author for this work

Hematology

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016–2019, forty patients were identified. Median age was 67 years (21–82), 60% males, median of 2(1–4) prior lines of treatment and 42% relapsed after allogeneic transplant. 62.5% of the patients received the venetoclax with hypomethylating agents and 22.5% with low dose cytarabine. Median follow-up was 5.5 months. Of the 29 patients who survived for more than two cycles of therapy, 22 (76%) achieved neutrophil recovery and 59% (n = 17) recovered also their platelet count. In 15 (52% of those who survived > 2 months), CR/CRi was confirmed by bone marrow examination. The median OS from venetoclax initiation of all the patients and of those who survived more than 2 months was 5.5 and 6.5 months, respectively. In conclusion, this study demonstrates that venetoclax is safe and active also in AML patients with advanced disease.

Original language	English
Pages (from-to)	2221-2225
Number of pages	5
Journal	Leukemia and Lymphoma
Volume	61
Issue number	9
DOIs	https://doi.org/10.1080/10428194.2020.1761964
State	Published - 28 Jul 2020

Keywords

Acute myeloid leukemia
refractory
relapse
venetoclax

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/10428194.2020.1761964

Cite this

Ganzel, C., Ram, R., Gural, A., Wolach, O., Gino-Moor, S., Vainstein, V., Nachmias, B., Apel, A., Koren-Michowitz, M., Pasvolsky, O., Yerushalmi, R., Danylesko, I., Cohen, Y., Peretz, G., Moshe, Y., Zektser, M., Yeganeh, S., Rowe, J. M., & Ofran, Y. (2020). Venetoclax is safe and efficacious in relapsed/refractory AML. Leukemia and Lymphoma, 61(9), 2221-2225. https://doi.org/10.1080/10428194.2020.1761964

@article{244c7fb26ad24b848764669b2f531deb,

title = "Venetoclax is safe and efficacious in relapsed/refractory AML",

abstract = "Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016–2019, forty patients were identified. Median age was 67 years (21–82), 60% males, median of 2(1–4) prior lines of treatment and 42% relapsed after allogeneic transplant. 62.5% of the patients received the venetoclax with hypomethylating agents and 22.5% with low dose cytarabine. Median follow-up was 5.5 months. Of the 29 patients who survived for more than two cycles of therapy, 22 (76%) achieved neutrophil recovery and 59% (n = 17) recovered also their platelet count. In 15 (52% of those who survived > 2 months), CR/CRi was confirmed by bone marrow examination. The median OS from venetoclax initiation of all the patients and of those who survived more than 2 months was 5.5 and 6.5 months, respectively. In conclusion, this study demonstrates that venetoclax is safe and active also in AML patients with advanced disease.",

keywords = "Acute myeloid leukemia, refractory, relapse, venetoclax",

author = "Chezi Ganzel and Ron Ram and Alexander Gural and Ofir Wolach and Sharon Gino-Moor and Vladimir Vainstein and Boaz Nachmias and Arie Apel and Maya Koren-Michowitz and Oren Pasvolsky and Ronit Yerushalmi and Ivetta Danylesko and Yosef Cohen and Galit Peretz and Yakir Moshe and Miri Zektser and Shay Yeganeh and Rowe, {Jacob M.} and Yishai Ofran",

note = "Publisher Copyright: {\textcopyright} 2020 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2020",

month = jul,

day = "28",

doi = "10.1080/10428194.2020.1761964",

language = "אנגלית",

volume = "61",

pages = "2221--2225",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "9",

}

Ganzel, C, Ram, R, Gural, A, Wolach, O, Gino-Moor, S, Vainstein, V, Nachmias, B, Apel, A, Koren-Michowitz, M , Pasvolsky, O , Yerushalmi, R , Danylesko, I, Cohen, Y, Peretz, G, Moshe, Y, Zektser, M, Yeganeh, S, Rowe, JM & Ofran, Y 2020, 'Venetoclax is safe and efficacious in relapsed/refractory AML', Leukemia and Lymphoma, vol. 61, no. 9, pp. 2221-2225. https://doi.org/10.1080/10428194.2020.1761964

TY - JOUR

T1 - Venetoclax is safe and efficacious in relapsed/refractory AML

AU - Ganzel, Chezi

AU - Ram, Ron

AU - Gural, Alexander

AU - Wolach, Ofir

AU - Gino-Moor, Sharon

AU - Vainstein, Vladimir

AU - Nachmias, Boaz

AU - Apel, Arie

AU - Koren-Michowitz, Maya

AU - Pasvolsky, Oren

AU - Yerushalmi, Ronit

AU - Danylesko, Ivetta

AU - Cohen, Yosef

AU - Peretz, Galit

AU - Moshe, Yakir

AU - Zektser, Miri

AU - Yeganeh, Shay

AU - Rowe, Jacob M.

AU - Ofran, Yishai

PY - 2020/7/28

Y1 - 2020/7/28

N2 - Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016–2019, forty patients were identified. Median age was 67 years (21–82), 60% males, median of 2(1–4) prior lines of treatment and 42% relapsed after allogeneic transplant. 62.5% of the patients received the venetoclax with hypomethylating agents and 22.5% with low dose cytarabine. Median follow-up was 5.5 months. Of the 29 patients who survived for more than two cycles of therapy, 22 (76%) achieved neutrophil recovery and 59% (n = 17) recovered also their platelet count. In 15 (52% of those who survived > 2 months), CR/CRi was confirmed by bone marrow examination. The median OS from venetoclax initiation of all the patients and of those who survived more than 2 months was 5.5 and 6.5 months, respectively. In conclusion, this study demonstrates that venetoclax is safe and active also in AML patients with advanced disease.

AB - Data from 11 Israeli centers, where venetoclax was used for relapsed/refractory AML after intensive chemotherapy, were retrospectively collected. During 2016–2019, forty patients were identified. Median age was 67 years (21–82), 60% males, median of 2(1–4) prior lines of treatment and 42% relapsed after allogeneic transplant. 62.5% of the patients received the venetoclax with hypomethylating agents and 22.5% with low dose cytarabine. Median follow-up was 5.5 months. Of the 29 patients who survived for more than two cycles of therapy, 22 (76%) achieved neutrophil recovery and 59% (n = 17) recovered also their platelet count. In 15 (52% of those who survived > 2 months), CR/CRi was confirmed by bone marrow examination. The median OS from venetoclax initiation of all the patients and of those who survived more than 2 months was 5.5 and 6.5 months, respectively. In conclusion, this study demonstrates that venetoclax is safe and active also in AML patients with advanced disease.

KW - Acute myeloid leukemia

KW - refractory

KW - relapse

KW - venetoclax

UR - http://www.scopus.com/inward/record.url?scp=85085324904&partnerID=8YFLogxK

U2 - 10.1080/10428194.2020.1761964

DO - 10.1080/10428194.2020.1761964

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 32420775

AN - SCOPUS:85085324904

SN - 1042-8194

VL - 61

SP - 2221

EP - 2225

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 9

ER -

Venetoclax is safe and efficacious in relapsed/refractory AML

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this